A review of latest clinical practice guidelines for the management of cancer-associated thrombosis |
| |
| Affiliation: | 1. Department of Internal Medicine, Hospital Universitario Virgen de Arrixaca, Murcia, Spain;2. Department Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale University School of Medicine, New Haven, CT, USA;3. Department of Internal Medicine, CHU Nantes, Nantes, France;4. Department of Internal Medicine, Hospital Universitario Reina Sofía, Córdoba, Spain;5. Department of Internal Medicine, Hospital Reina Sofía, Tudela, Navarra, Spain;6. Vascular Medicine and Haemostasis, University of Leuven, Leuven, Belgium;7. Department of Internal Medicine, Hospital San Pedro de Alcántara, Cáceres, Spain;8. Department of Internal Medicine and Emergency, Parc Sanitari Sant Joan de Déu-Hospital General, Barcelona, Spain;9. Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain;10. Chair for the Study of Thromboembolic Disease, Faculty of Health Sciences, UCAM - Universidad Católica San Antonio de Murcia, Universidad Autónoma de Barcelona, Spain |
| |
| Abstract: | The management of cancer-associated thrombosis (CAT) poses unique challenges to healthcare professionals. While low‐molecular weight heparins (LMWHs) have long been the gold standard for both the primary and secondary prevention of CAT, results from large randomized controlled trials assessing the benefit of direct oral anticoagulants (DOACs) in both settings have resulted in some paradigm shifts. Herein, we review and compare recommendations from the latest authoritative clinical practice guidelines (CPGs) for the management of CAT and summarize the most recent evidence on available treatment options. A rigorous methodology was used to select high quality CPGs and compare the recommendations across CPGs. Only CPGs focusing on the management of CAT developed by a multidisciplinary international working group and issued or endorsed by national or international scientific societies, or government organizations were eligible for inclusion. The quality of selected CPGs was assessed using the Appraisal of Guidelines, Research, and Evaluation II (AGREE II) tool. Four CPGs met the inclusion criteria, including the International Initiative on Thrombosis and Cancer (ITAC), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the National Comprehensive Cancer Network (NCCN). |
| |
| Keywords: | Venous thromboembolism Cancer Guidelines Prevention Treatment |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
